Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hamilton, R. A.
Right arrow Articles by Kremer, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamilton, R. A.
Right arrow Articles by Kremer, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The British Journal of Rheumatology, Vol 36, 86-90, Copyright © 1997 by British Society for Rheumatology

ORIGINAL PAPERS

Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis

RA Hamilton and JM Kremer
Albany College of Pharmacy, NY 12208, USA.

In order to compare the relative bioavailability of orally administered methotrexate (MTX) with i.m. administration in patients with rheumatoid arthritis, we compared the pharmacokinetics of MTX at both the usual starting dose of 7.5 mg and at higher established maintenance dosages in 21 patients. Pharmacokinetic measures were repeated approximately 6 and 18 months after baseline while patients consumed their usual maintenance doses of MTX (17.0 +/- 3.8 mg). The relative bioavailability of the usual maintenance dose of MTX was reduced by 13.5% compared with the initial dose of 7.5 mg (P = 0.026). Area under the serum concentration vs time curve (AUC) was significantly reduced with oral vs i.m. administration at usual maintenance doses (decrease of 0.729 mumol.h/l by oral administration, P = 0.027), but not at a 7.5 mg dose of MTX. Clinicians using MTX should not assume constant and complete bioavailability across the dose range used to treat patients with rheumatoid arthritis. Our observations explain the reported clinical success of switching from an oral to a parenteral route of administration in patients receiving maintenance doses of MTX.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. Bharadwaj, S. Agrawal, M. Batley, and A. Hammond
Use of parenteral methotrexate significantly reduces the need for biological therapy
Rheumatology, February 1, 2008; 47(2): 222 - 222.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. Metzler, N. Miehle, K. Manger, C. Iking-Konert, K. de Groot, B. Hellmich, W. L. Gross, E. Reinhold-Keller, and for the German Network of Rheumatic Diseases
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis
Rheumatology, July 1, 2007; 46(7): 1087 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S P L Travis, E F Stange, M Lemann, T Oresland, Y Chowers, A Forbes, G D'Haens, G Kitis, A Cortot, C Prantera, et al.
European evidence based consensus on the diagnosis and management of Crohn's disease: current management
Gut, March 1, 2006; 55(suppl_1): i16 - i35.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. K. Moitra, J. M. Ledingham, R. G. Hull, F. C. McCrae, A. L. Thomas, R. Shaban, and K. R. MacKay
Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease
Rheumatology, February 1, 2005; 44(2): 256 - 257.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J Wegrzyn, P Adeleine, and P Miossec
Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis
Ann Rheum Dis, October 1, 2004; 63(10): 1232 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M J Carter, A J Lobo, and S P L Travis
Guidelines for the management of inflammatory bowel disease in adults
Gut, September 1, 2004; 53(suppl_5): v1 - v16.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. J. Griffin and F. Erkeller-Yuksel
Parenteral methotrexate should be given before biological therapy
Rheumatology, May 1, 2004; 43(5): 678 - 678.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. J. Bingham, M. H. Buch, S. Lindsay, A. Pollard, J. White, and P. Emery
Parenteral methotrexate should be given before biological therapy
Rheumatology, August 1, 2003; 42(8): 1009 - 1010.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A Rozin, D Schapira, A Balbir-Gurman, Y Braun-Moscovici, D Markovits, D Militianu, and M A Nahir
Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate
Ann Rheum Dis, August 1, 2002; 61(8): 756 - 757.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
G BURBAGE, R GUPTA, K LIM, and D MULHERIN
Intramuscular methotrexate in inflammatory rheumatic disease
Ann Rheum Dis, December 1, 2001; 60(12): 1156 - 1156.
[Full Text] [PDF]

Home page
 GutHome page
A B HAWTHORNE
Methotrexate: a useful alternative in Crohn's disease?
Gut, July 1, 2001; 49(1): 9 - 10.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. M. Kremer
Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arthritis
Ann Intern Med, April 17, 2001; 134(8): 695 - 706.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A OSMAN and D MULHERIN
Is parenteral methotrexate worth trying?
Ann Rheum Dis, April 1, 2001; 60(4): 432 - 432.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.